BTX-A51 for advanced solid tumors and breast cancer patients
Part of Cancer, Skin clinical trials.
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign informed consent
- Your cancer is advanced (incurable or metastatic) and either didn’t respond to standard treatment, can’t be tolerated, or has no standard treatment
- You must have measurable cancer on scans/tests (measurable disease)
- Your liver, kidneys, and blood counts must be “adequate” for treatment
- If you could get pregnant: you must not be pregnant and use very effective birth control during the study and for about 3 months after the last dose
- If you are male and have sex with a woman who could get pregnant: you must use a barrier birth control method during the study and for about 3 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This study tests a new drug called XTX501 for people with advanced non-small cell lung cancer (NSCLC) or other solid tumors. The drug may help the immune system fight cancer, and the study aims to see if it is safe and effective.
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.